Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
3.890
-0.320 (-7.60%)
At close: Jun 27, 2025, 4:00 PM
3.980
+0.090 (2.31%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 3 or 10.71% compared to the previous year.
Employees
31
Change (1Y)
3
Growth (1Y)
10.71%
Revenue / Employee
n/a
Profits / Employee
-$1,335,452
Market Cap
299.98M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CRVS News
- 24 days ago - Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - GlobeNewsWire
- 4 weeks ago - Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga
- 7 weeks ago - Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - GlobeNewsWire
- 2 months ago - Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - GlobeNewsWire
- 2 months ago - Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - GlobeNewsWire